GURBF:OTCMKTS
Guerbet SA
0.00%
(0.00) 1రో
7 జన, 1:19:10 AM GMT-4 · USD
search
అన్ని చిహ్నాలు
1రో
5రో
1నె
6నె
YTD
1సం
5సం
గరి
| చిహ్నం | ధర | మార్చు | % మార్చు |
|---|
insights_autoGURBFకు సంబంధించి టాప్ గణాంకాలు జెనరేట్ అవుతున్నాయి...
మార్కెట్ క్యాపిటలైజేషన్
౧౫౨.౭౦మి
వాల్యూమ్
౦.౦౦
ఉద్యోగుల సంఖ్య
౩వే
వార్తల కథనాలు
వెబ్ అంతటా ఉండే సోర్స్ల నుండి
Simply Wall Street
·
13 నిమిషాల క్రితం
Applied Optoelectronics Expands U.S. Footprint To Ride AI Photonics Wave
Morningstar Canada
·
16 నిమిషాల క్రితం
iShares Edge S&P 500 Minimum Volatility Offers a Smoother Ride Through US Stock Markets
MarketBeat
·
28 నిమిషాల క్రితం
Nayax Ltd. (NASDAQ:NYAX) Given Consensus Recommendation of "Hold" by Brokerages
TechStock²
·
29 నిమిషాల క్రితం
US Stock Futures Slip Before The Bell As Oil Spike Tests Record S&P 500 Rally
ప్రొఫైల్
Guerbet is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration approved Guerbet Group's Elucirem, an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina and at three of its French factories.
An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player." Wikipedia
Guerbet SA గురించిన వివరాలు
AI కంటెంట్లో తప్పులు ఉండవచ్చు. మరింత తెలుసుకోండి